{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041292","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.153702+00:00","generated_at":"2026-06-11T18:33:06.865845+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AVITA Medical Q2 commercial revenue up 42% to $11.7M; raises FY2023 guidance to $51-53M; two FDA approvals","bullets":["Commercial revenue $11.7M (+42% YoY); net loss $0.41/share vs $0.25 loss in prior year.","FDA approved RECELL for full-thickness skin defects (June 7) and vitiligo repigmentation (June 16).","FY2023 revenue guidance raised to $51-53M from prior $49-51M; Q3 guidance $13-14M.","RECELL GO PMA supplement submitted; FDA decision expected by December 27, 2023.","Cash $68.8M, no debt; gross margin guided 83-85% for FY2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041292","json":"https://secwatch.observer/filing/0000950170-23-041292.json","markdown":"https://secwatch.observer/filing/0000950170-23-041292.md","text":"https://secwatch.observer/filing/0000950170-23-041292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000095017023041292/0000950170-23-041292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000095017023041292/rcel-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:33:06.865845+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9aa7e9f735a920b2266fbd352011c4e35f462d23","claim":"AVITA Medical, Inc. reported second quarter June 30, 2023 results: revenue $11.7 million, net income $10.4 million, EPS $0.41 per share. Guidance raised.","evidence_excerpt":"Commercial revenue of $11.7 million, a 42% increase compared to $8.2 million for the same period in 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1762303/000095017023041292/0000950170-23-041292-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter June 30, 2023"},{"label":"Revenue","value":"$11.7 million"},{"label":"Net income","value":"$10.4 million"},{"label":"EPS","value":"$0.41 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}